#USA #Astrana Health #NASDAQ ASTH #Alhambra #Q1 2026 Results

Astrana Health, Inc. Reports First Quarter 2026 Results

Astrana Health, Inc. has made a significant announcement regarding its consolidated financial results for the first quarter ending March 31, 2026, showcasing strong performance across several key metrics. The company reported a total revenue of $965.1 million, representing an impressive 56% year-over-year increase, compared to $620.4 million in Q1 of 2025.

Financial Highlights

Astrana's revenue primarily comes from its Care Partners segment, which generated $909.7 million, up 51% from $601.0 million in the prior year. The net income attributable to Astrana showed a remarkable rise, reaching $14.4 million, a 116% increase from $6.7 million a year prior. This translates to a diluted earnings per share (EPS) of $0.29, up 107% from the previous $0.14.

The Adjusted EBITDA for Q1 2026 was $66.3 million, marking an 82% increase from $36.4 million in the same quarter last year. Furthermore, Astrana's free cash flow saw a staggering growth of 372%, totaling $64.1 million, a dramatic leap from just $13.6 million in Q1 2025.

Brandon Sim, President and CEO of Astrana, remarked on the company's strong start to 2026, highlighting disciplined growth and strong performance in medical costs as factors contributing to their success. He noted the integration of care delivery and data management as crucial in maintaining their competitive edge amidst the dynamic nature of the healthcare environment.

Recent Operating Highlights

In addition to strong financials, Astrana also reported operational achievements such as converting key contracts into full-risk arrangements. Approximately 80% of their Care Partners capitation revenue and about 40% of consolidated membership are now in full-risk contracts, reflecting a strategic shift towards value-based care.

Moreover, the launch of Astrana's delegated full-risk model in Texas has contributed to expanding their Medicare Advantage membership to over 14,000 members. This transition showcases their commitment to delivering high-quality, accessible healthcare to their members.

Astrana also announced the ongoing efforts to improve its financial structure, with net leverage declining to approximately 2.3x on a pro forma trailing twelve-month basis, a significant improvement that positions the company favorably for future growth.

Another highlight includes the recognition of Foothill Regional Medical Center (FRMC), which received the 2026 Patient Safety Excellence Award for the fourth consecutive year and was named one of America's 100 Best Hospitals for Joint Replacement. This accolade underscores Astrana's commitment to clinical quality and patient outcomes.

Looking Ahead: 2026 Guidance

For the upcoming quarter ending June 30, 2026, Astrana has set a revenue guidance range of $965 to $1,000 million and an Adjusted EBITDA forecast of $65 to $70 million. The company reaffirms its expectation of total revenue for the year ending December 31, aiming between $3,800 and $4,100 million, with a corresponding Adjusted EBITDA range of $250 to $280 million.

As Astrana Health continues to innovate within the healthcare sector, its strategic focus on comprehensive care delivery systems and data integration positions it well to respond to ongoing challenges and opportunities in the market, ensuring sustainable growth and enhanced patient outcomes for years to come.